Burzynski: BRAINSTEM GLIOMAs (DBSG)

� � � � � � � � � � � � � � � � �
% and # of Patients Resolving or Stabilizing Disease = Complete Response + Partial Response + Stable Disease
——————————————————————
80% / 8 – 3/1996 Antineoplastons Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA (3/1996 – 5/1999 enrolled) 2003
�
75% / 21.-.12/2009 Antineoplastons: Protocol – BRAINSTEM GLIOMAs (DBSG) (BT-11)
�
74% / 23.-.2003 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) BT-11 Special Exception (SE) 10/2004
�
70% / 6 – 2006 Antineoplastons – children aged <4 years diagnosed with Diffuse Intrinsic BRAIN STEM GLIOMA (DBSG)
�
70% / 7 – 7/2005 Antineoplastons – Protocol – BT-11 BRAIN STEM GLIOMA (BSG)
�
68% / 35.-.12/2009 Antineoplastons: Protocol – BRAINSTEM GLIOMAs: BT-11 Special Exception (SE)
�
66% / 19.-.2003 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) BT-11 10/2004
�
64% / 6 – 3/1996 Antineoplastons: Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 Special Exception (SE) (Pg. 99)
�
61% / 11.-.3/2006 (7/12/1988 – 11/13/2003 as of 6/10/2005) Antineoplastons – Protocol – recurrent diffuse intrinsic GLIOBLASTOMAS and ANAPLASTIC ASTROCYTOMAS of the BRAINSTEM high-grade pathology (HBSG)
�
60% / 12.-.4/2007 Antineoplastons: Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG) (BT-11)
�
53% / 10.-.10/2006 Antineoplastons: Protocol – BT-11 BRAINSTEM GLIOMAS and MULTICENTRIC TUMORS (MBSG)
�
47% / 21.–.3/2006 Antineoplastons patients with recurrent and progressive Diffuse Intrinsic Brain Stem Glioma (DBSG)
�
33% – 1999 standard radiation therapy in combination with chemotherapy (RAT) (Mandell et al.) (6/1992 – 10/1997)
======================================
% and # of Patients Showing Objective Response = Complete Response + Partial Response
——————————————————————
50% / 5 – 2003 Protocol – Antineoplastons recurrent diffuse intrinsic BRAIN STEM GLIOMAs: BT-11 Special Exception (SE) 9/2004
�
50% / 5 – 2003 Antineoplastons Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA (3/1996 – 5/1999 enrolled)
�
45% / 13.-.2003 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) BT-11 10/2004
�
40% / 8 – 4/2007 Antineoplastons: Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG) (BT-11)
�
33% – 3/15/1999 children with newly diagnosed diffuse intrinsic BRAIN STEM TUMORS: standard radiation therapy in combination with chemotherapy (RAT) (Mandell et al (6/1992–10/1997)
�
32% / 9 – 12/2009 Antineoplastons: Protocol – BRAINSTEM GLIOMAs (DBSG) (BT-11)
�
30% / 3 – 2006 Antineoplastons – children aged <4 years diagnosed with Diffuse Intrinsic BRAIN STEM GLIOMA (DBSG)
�
30% / 3 – 7/2005 Antineoplastons – Protocol – BT-11 BRAIN STEM GLIOMA (BSG)
�
22% / 4 – 3/2006 (7/12/1988 – 11/13/2003 as of 6/10/2005) Antineoplastons – Protocol – recurrent diffuse intrinsic GLIOBLASTOMAS and ANAPLASTIC ASTROCYTOMAS of the BRAINSTEM high-grade pathology (HBSG)
�
22% / 7 – 2003 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) BT-11 Special Exception (SE) 10/2004
�
20% / 16.-.12/2009 Antineoplastons: COMBINED – patients with BRAINSTEM GLIOMA BT-11 (ST) + BT-11 Special Exception (SE)
�
16% / 3 – 10/2006 Antineoplastons: Protocol – BT-11 BRAINSTEM GLIOMAS and MULTICENTRIC TUMORS (MBSG)
�
14% / 7 – 12/2009 Antineoplastons: Protocol – BRAINSTEM GLIOMAs: BT-11 Special Exception (SE)
�
9% / 1 – 3/1996 Antineoplastons Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 Special Exception (SE) (Pg. 99)
======================================
% and # of Patients Showing Complete Response
——————————————————————
30% / 6 – 4/2007 Antineoplastons: Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG) (BT-11)
�
30% / 3 – 2006 Antineoplastons – children aged <4 years diagnosed with Diffuse Intrinsic BRAIN STEM GLIOMA (DBSG)
�
30% / 3 – 7/2005 Antineoplastons – Protocol – BT-11 BRAIN STEM GLIOMA (BSG)
�
27% / 8 – 3/2006 Antineoplastons patients with recurrent and progressive Diffuse Intrinsic Brain Stem Glioma (DBSG)
�
24% / 7 – 2003 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) BT-11 10/2004
�
20% / 2 – 2003 Antineoplastons Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA (3/1996 – 5/1999 enrolled)
�
20% / 2 – 3/1996 Antineoplastons Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pg. 99)
�
18% / 5 – 12/2009 Antineoplastons: Protocol – BRAINSTEM GLIOMAs (DBSG) (BT-11)
�
16% / 5 – 2003 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) BT-11 Special Exception (SE) 10/2004
�
12.5% / 10 – Antineoplastons: COMBINED – patients with BRAINSTEM GLIOMA BT-11 (ST) + BT-11 Special Exception (SE)
�
11% / 2 – 10/2006 Antineoplastons: Protocol – BT-11 BRAINSTEM GLIOMAS and MULTICENTRIC TUMORS (MBSG)
�
11% / 2 – 3/2006 (7/12/1988 – 11/13/2003 as of 6/10/2005) Antineoplastons – Protocol – recurrent diffuse intrinsic GLIOBLASTOMAS and ANAPLASTIC ASTROCYTOMAS of the BRAINSTEM high-grade pathology (HBSG)
�
10% / 5 – 12/2009 Antineoplastons – Protocol – BRAINSTEM GLIOMAs: BT-11 Special Exception (SE)
�
9% / 1 – 3/1996 Antineoplastons Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 Special Exception (SE) (Pg. 99)
�
2% – 3/15/1999 children with newly diagnosed diffuse intrinsic BRAIN STEM TUMORS: standard radiation therapy in combination with chemotherapy (RAT) (Mandell et al (6/1992 – 10/1997))
======================================
% and # of Patients Showing Partial Response
——————————————————————
31% – 3/15/1999 children with newly diagnosed diffuse intrinsic BRAIN STEM TUMORS: standard radiation therapy in combination with chemotherapy (RAT) (Mandell et al (6/1992 – 10/1997)
�
30% / 3 – 2003 Antineoplastons Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA (3/1996 – 5/1999 enrolled)
�
30% / 3 – 3/1996 Antineoplastons Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pg. 99)
�
21% / 6 – 2003 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) BT-11 10/2004
�
20% / 6 – 3/2006 Antineoplastons patients with recurrent and progressive Diffuse Intrinsic Brain Stem Glioma (DBSG)
�
14% / 4 – 12/2009 Antineoplastons: Protocol – BRAINSTEM GLIOMAs (DBSG) (BT-11)
�
11% / 2 – 3/2006 (7/12/1988 – 11/13/2003 as of 6/10/2005) Antineoplastons – Protocol – recurrent diffuse intrinsic GLIOBLASTOMAS and ANAPLASTIC ASTROCYTOMAS of the BRAINSTEM high-grade pathology (HBSG)
�
10% / 2 – 4/2007 Antineoplastons: Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG) (BT-11)
�
7.5% / 6 – 12/2009 Antineoplastons: COMBINED – patients with BRAINSTEM GLIOMA BT-11 (ST) + BT-11 Special Exception (SE)
�
6% / 2 – 2003 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) BT-11 Special Exception (SE) 10/2004
�
5% / 1 – 10/2006 Antineoplastons: Protocol – BT-11 BRAINSTEM GLIOMAS and MULTICENTRIC TUMORS (MBSG)
�
4% / 2 – 12/2009 Antineoplastons – Protocol – BRAINSTEM GLIOMAs: BT-11 Special Exception (SE)
======================================
% and # of Patients Showing Stable Disease
——————————————————————
55% / 5 – 3/1996 Antineoplastons Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 Special Exception (SE) (Pg. 99)
�
54% / 28.-.12/2009 Antineoplastons – Protocol – BRAINSTEM GLIOMAs: Special Exception (SE)
�
52% / 16.-.2003 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) BT-11 Special Exception (SE) 10/2004
�
43% / 12.-.12/2009 Antineoplastons: Protocol – BRAINSTEM GLIOMAs (DBSG) (BT-11)
�
40% / 4 – 2006 Antineoplastons – children aged <4 years diagnosed with Diffuse Intrinsic BRAIN STEM GLIOMA (DBSG)
�
40% / 4 – 7/2005 Antineoplastons – Protocol – BT-11 BRAIN STEM GLIOMA (BSG)
�
39% / 7 – 3/2006 (7/12/1988 – 11/13/2003 as of 6/10/2005) Antineoplastons – Protocol – recurrent diffuse intrinsic GLIOBLASTOMAS and ANAPLASTIC ASTROCYTOMAS of the BRAINSTEM high-grade pathology (HBSG)
�
37% / 7 – 10/2006 Antineoplastons: Protocol – BT-11 BRAINSTEM GLIOMAS and MULTICENTRIC TUMORS (MBSG)
�
30% / 3 – 2003 Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMAs: BT-11 Special Exception (SE) 9/2004
�
30% / 3 – 2003 Antineoplastons Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA (3/1996 – 5/1999 enrolled
�
30% / 3 – 3/1996 Antineoplastons Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pg. 99)
�
23% / 7 – 3/2006 Antineoplastons patients with recurrent and progressive Diffuse Intrinsic Brain Stem Glioma (DBSG)
�
21% / 6 – 2003 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) BT-11 10/2004
�
20% / 4 – 4/2007 Antineoplastons: Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG) (BT-11)
======================================
% and # of Patients Showing Progressive Disease
——————————————————————
47% / 9 – 10/2006 Antineoplastons: Protocol – BT-11 BRAINSTEM GLIOMAS and MULTICENTRIC TUMORS (MBSG)
�
40% / 8 – 4/2007 Antineoplastons: Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG) (BT-11)
�
36% / 4 – 3/1996 Antineoplastons Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 Special Exception (SE) (Pg. 99)
�
34% / 10.-.2003 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) BT-11 10/2004
�
32% / 17.–.12/2009 Antineoplastons – Protocol – BRAINSTEM GLIOMAs: BT-11 Special Exception (SE)
�
30% / 9 – 3/2006 Antineoplastons patients with recurrent and progressive Diffuse Intrinsic Brain Stem Glioma (DBSG)
�
30% / 3 – 2006 Antineoplastons – children aged <4 years diagnosed with Diffuse Intrinsic BRAIN STEM GLIOMA (DBSG)
�
30% / 3 – 7/2005 Antineoplastons – Protocol – BT-11 BRAIN STEM GLIOMA (BSG)
�
26% / 8 – 2003 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) BT-11 Special Exception (SE) 10/2004
�
25% / 7 – 12/2009 Antineoplastons: Protocol – BRAINSTEM GLIOMAs (DBSG) (BT-11)
�
20% / 2 – 2003 Protocol – Antineoplastons recurrent diffuse intrinsic BRAIN STEM GLIOMAs: BT-11 Special Exception (SE) 9/2004
�
20% / 2 – 2003 Antineoplastons Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA (3/1996 – 5/1999 enrolled
�
20% / 2 – 3/1996 Antineoplastons Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pg. 99)
� � � � � � � � � � � � � � � � �

� � � � � � � � � � � � � � � � �
======================================
Maximum Survival for Patient with recurrent, diffuse, intrinsic anaplastic ASTROCYTOMA:
——————————————————————
17+ years (approaching 18 years) – 3/2006 Antineoplastons: BRAINSTEM GLIOMA (BSG) (Pgs. 40 and 44-45)
======================================
Maximum Survival:
——————————————————————
15.5+ years – 10/2004 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG): (high-grade diffuse intrinsic BRAIN STEM GLIOMA (DBSG) recurrent after radiation and chemotherapy)
======================================
Maximum Survival (MS):
——————————————————————
12.5+ years – 6/1/2003 Antineoplastons: Protocol – HIGH-GRADE GLIOMA (Pg. 53)
======================================
Maximum Survival:
——————————————————————
12+ years – 4/2007 Antineoplastons: Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG) BT-11
======================================
Maximum Survival:
——————————————————————
11 years – 10/2004 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG): Special Exception (SE): (high-grade diffuse intrinsic BRAIN STEM GLIOMA (DBSG) recurrent after radiation and chemotherapy):
======================================
Maximum Survival Rate:
——————————————————————
9+ years – 10/2006 Antineoplastons: Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG)
======================================
Maximum Survival (MS):
——————————————————————
7.5+ years – 6/1/2003 Antineoplastons: Protocol – BT-11 BRAIN STEM GLIOMA 2004 (Pg. 51)
======================================
Longest Survival (the Patients are currently alive):
——————————————————————
7+ years – 3/2004 Antineoplastons: Protocol – subgroup very difficult to treat recurrent diffuse intrinsic BRAIN STEM GLIOMA (Pg. 52)
======================================
Maximum Survival (MS):
——————————————————————
7+ years – 2006 Antineoplastons (ANP) – children aged <4 years diagnosed with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) treated with ANP (Pg. 173)
======================================
Median Overall Survival from Diagnosis (OSD):
——————————————————————
6.3 years – 6/1/2003 Antineoplastons: Protocols – LOW-GRADE GLIOMA IN CHILDREN 2004 (Pg. 50)
======================================
Maximum Survival (MS):
——————————————————————
6+ years – 7/2005
Antineoplastons: children less than 4 years old with inoperable BRAIN STEM GLIOMAs (BSG) BT-11 (study and Special Exception (SE))
======================================
Patient with GLIOBLASTOMA:
——————————————————————
(6+ years – Patient with recurrent, diffuse, intrinsic GLIOBLASTOMA MULTIFORME (GBM))
======================================
Survival in recurrent diffuse intrinsic GLIOBLASTOMAS and anaplastic ASTROCYTOMAS of the BRAINSTEM in a small group of Patients:
——————————————————————
5+ years – 3/2006 Antineoplastons: BRAINSTEM GLIOMA (BSG) (Pgs. 40 and 44-45)
======================================
Patient with GLIOBLASTOMA:
——————————————————————
5+ years – 3/2006 Antineoplastons: BRAINSTEM GLIOMA (BSG) (Pgs. 40 and 44-45)
======================================
5+ years Alive and Tumor Free since Initial Diagnosis:
——————————————————————
2 / 17% – 2003 Antineoplastons: Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pgs. 91-92)
======================================
From start of Treatment:
——————————————————————
5+ years – 1 alive – 2003 Antineoplastons Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pgs. 91-92)
======================================
5+ year patients survived
——————————————————————
9 / 30% – 2006 Antineoplastons (ANP) recurrent and progressive diffuse intrinsic BRAINSTEM GLIOMA (DBSG)
======================================
5 year Overall Survival (OS):
——————————————————————
30% / 6 – 4/2007 Antineoplastons ((ANP): Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG) BT-11
======================================
5 year Overall Survival (OS) (%) – Efficacy:
——————————————————————
9 / 30% – 2006 Antineoplastons (ANP): Treatments for Astrocytic Tumors – recurrent and progressive tumor: Treatment of diffuse, intrinsic BRAINSTEM GLIOMA in children (Pg. 172)
======================================
Overall Survival (Survival: Special Exception (SE))
——————————————————————
7 / 24% – 5 years: 10/2004 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG)
======================================
5 year Overall Survival:
——————————————————————
22% – 3/2006 Antineoplastons: Patients with high-grade, recurrent and progressive BRAINSTEM GLIOMAS (BSG) (Pgs. 40 and 44-45)
======================================
5-year Survival rate:
——————————————————————
2 / 20% – 2006 Antineoplastons (ANP) – children aged <4 years diagnosed with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) treated with ANP (Pg. 173)
======================================
5 year Overall Survival (OS) (%) – Efficacy:
——————————————————————
2 / 20% – 2006 Antineoplastons (ANP) – recurrent and progressive (RPS) tumors in children aged <4y (Pg. 172): children less than 4 years old with inoperable BRAIN STEM GLIOMAS 2005
======================================
5 year Overall Survival:
——————————————————————
2 / 20% – 7/2005 Antineoplastons: children less than 4 years old with inoperable BRAIN STEM GLIOMAs (BSG) BT-11 (study and Special Exception (SE))
======================================
Overall Survival (Survival: Special Exception (SE))
——————————————————————
5 / 16% – 5 years: 10/2004 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG): Special Exception (SE)
======================================
5 year Overall Survival Rate (OS):
——————————————————————
3 / 16% – 10/2006 Antineoplastons: Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG)
======================================
5 year Overall Survival (OS):
——————————————————————
0% – 3/15/1999 standard radiation therapy in combination with chemotherapy (RAT) (Mandell et al.) (6/1992–10/1997) children with newly diagnosed diffuse intrinsic BRAIN STEM TUMORS: results of pediatric oncology group
======================================
From start of Treatment:
——————————————————————
4+ years – 1 alive – 2003 Antineoplastons Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pgs. 91-92)
======================================
Median Overall Survival from Diagnosis (OSD):
——————————————————————
3 years – 6/1/2003 Antineoplastons: Protocol – HIGH-GRADE GLIOMA (Pg. 53)
======================================
with treatment, may approach:
——————————————————————
3 years – (Pg. 53)
======================================
Median Survival Time (MST):
——————————————————————
26.3 months (2 years 2.3 months) – 2006 Antineoplastons (ANP) – recurrent and progressive (RPS) tumors in children aged <4y (Pg. 172): children less than 4 years old with inoperable BRAIN STEM GLIOMAS 2005
======================================
2+ year patients survived
——————————————————————
12 / >40% – 2006 Antineoplastons (ANP) recurrent and progressive diffuse intrinsic BRAINSTEM GLIOMA (DBSG)
======================================
Most Patients with Newly Diagnosed High-Grade BRAIN STEM GLIOMAS (HBSG) don’t Survive more than:
——————————————————————
2+ years – (Pgs. 40 and 45-46)
======================================
2-year Survival rate:
——————————————————————
6 / 60% – 2006 Antineoplastons (ANP) – children aged <4 years diagnosed with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) treated with ANP (Pg. 173)
======================================
2 year Overall Survival (OS) (%) – Efficacy:
——————————————————————
6 / 60% – 2006 Antineoplastons (ANP) – recurrent and progressive (RPS) tumors in children aged <4y (Pg. 172): children less than 4 years old with inoperable BRAIN STEM GLIOMAS 2005
======================================
2 year Overall Survival:
——————————————————————
5 / 50% – 7/2005
Antineoplastons: children less than 4 years old with inoperable BRAIN STEM GLIOMAs (BSG) BT-11 (study and Special Exception (SE))
======================================
2 year Overall Survival (OS) (%) – Efficacy:
——————————————————————
30 / 46.7% – 2006 next best traditional standard of care study
======================================
2 year Overall Survival (OS) (%) – Efficacy:
——————————————————————
14 / 46.7% – 2006 Antineoplastons (ANP): Treatments for Astrocytic Tumors – recurrent and progressive tumor: Treatment of diffuse, intrinsic BRAINSTEM GLIOMA in children (Pg. 172)
======================================
2 year Overall Survival (Survival: Special Exception (SE))
——————————————————————
13 / 45% – 10/2004 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG)
======================================
2 year Survival:
——————————————————————
42% – 6/1/2003 Antineoplastons: Protocol – BRAIN STEM GLIOMA 2004 (Pgs. 52-53)
======================================
2 year Patients Surviving:
——————————————————————
42% – 6/1/2003 Antineoplastons: Protocol – BRAIN STEM GLIOMA 2004 (Pgs. 52–53)
======================================
2 year Overall Survival (OS):
——————————————————————
40% / 8 – 4/2007 Antineoplastons (ANP): Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG) BT-11
======================================
2 year Overall Survival:
——————————————————————
39% – 3/2006 Antineoplastons: Patients with high-grade, recurrent and progressive BRAINSTEM GLIOMAS (BSG) (Pgs. 40 and 44-45)
======================================
2 year Survival:
——————————————————————
4 / 33.3% – 2003 Antineoplastons Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11
(Pgs. 91-92)
======================================
2 year Overall Survival Rate (OS):
——————————————————————
6 / 32% – 10/2006 Antineoplastons: Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG)
======================================
2 year Overall Survival (Survival: Special Exception (SE))
——————————————————————
10 / 32% – 10/2004 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG): Special Exception (SE)
======================================
Progression-Free Survival Rate (PFS):
——————————————————————
3 / 16% – 2 years: 10/2006 Antineoplastons: Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG)
======================================
2 year Survival:
——————————————————————
Less than 10% – standard radiation therapy: for newly diagnosed diffuse intrinsic BRAIN STEM GLIOMA (DBSG)
======================================
2 year Patients Surviving:
——————————————————————
9 / 7.1% – 3/15/1999 ARM 1: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
======================================
2 year Patients Surviving:
——————————————————————
9 / 7.1% – ARM 1: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 3/15/1999 (Pg. 58)
======================================
2 year Overall Survival (OS):
——————————————————————
7% – 3/15/1999 standard radiation therapy in combination with chemotherapy (RAT) (Mandell et al.) (6/1992–10/1997) children with newly diagnosed diffuse intrinsic BRAIN STEM TUMORS: results of pediatric oncology group
======================================
2 year Patients Surviving:
——————————————————————
4 / 6.7% – 3/15/1999 ARM 2: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
======================================
2 year Patients Surviving:
——————————————————————
4 / 6.7% – ARM 2: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 3/15/1999 (Pg. 58)
======================================
Most Patients with BRAINSTEM GLIOMA fail standard radiation therapy and chemotherapy and don’t survive longer:
——————————————————————
2 years – (Pgs. 40 and 45-46)
======================================
Median Survival Time (MST):
——————————————————————
19.9 months (1 year 7.9 months) – 2006 Antineoplastons (ANP): Treatments for Astrocytic Tumors – recurrent and progressive tumor: Treatment of diffuse, intrinsic BRAINSTEM GLIOMA in children (Pg. 172)
======================================
Median Survival Time (MST):
——————————————————————
19.9 months (1 year 7.9 months) – 2006 next best traditional standard of care study
======================================
Median Survival without Treatment
——————————————————————
17 months (1 year 5 months) – (Pg. 53)
======================================
Median Survival (MST):
——————————————————————
16.4 months (1 year 4.4 months) – 4/2007 Antineoplastons(ANP): Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG) BT-11
======================================
Median Overall Survival from Diagnosis (OSD):
——————————————————————
13.7 months (1 year 1.7 months) – Antineoplastons 6/1/2003 – Protocol – BRAIN STEM GLIOMA (Pg. 51)
======================================
Median Overall Survival from Diagnosis (OSD):
——————————————————————
13.7 months (1 year 1.7 months) – 6/1/2003 Antineoplastons: Protocol – BT-11 BRAIN STEM GLIOMA 2004 (Pg. 51)
======================================
Median Overall Survival from start of Treatment (OST):
——————————————————————
1.15 years – 6/1/2003 Antineoplastons: Protocol – HIGH-GRADE GLIOMA (Pg. 53)
======================================
1 year Overall Survival Rate (OS):
——————————————————————
10 / 53% – 10/2006 Antineoplastons: Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG)
======================================
1 year Progression-Free Survival (PFS):
——————————————————————
12 / 41% – 10/2004 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG)
======================================
1 year Patients Surviving:
——————————————————————
40 / 30.9% – ARM 1: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992 – 10/1997) 3/15/1999 (Pg. 58)
======================================
1 year Progression-Free Survival (PFS):
——————————————————————
9 / 29% – 10/2004 Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG): Special Exception (SE)
======================================
1 year Patients Surviving:
——————————————————————
40 / 30.9% – 3/15/1999 ARM 1: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
======================================
1 year Patients Surviving:
——————————————————————
17 / 27.0% – 3/15/1999 ARM 2: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
======================================
Progression-Free Survival (PFS):
——————————————————————
12 months (1 year) – 6/1/2003 Antineoplastons: Protocol – HIGH-GRADE GLIOMA 2004 (Pg. 53)
======================================
% of Objective Response (OR) Patients hadn’t had Progression:
——————————————————————
61% – 6/1/2003 Antineoplastons: Protocol – HIGH-GRADE GLIOMA 2004 (Pg. 53)
======================================
1 year Patients Surviving:
——————————————————————
17 / 27.0% – ARM 2: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992 – 10/1997) 3/15/1999 (Pg. 58)
======================================
Progression-Free Survival Rate (PFS):
——————————————————————
5 / 26% – 1 year: 10/2006 Antineoplastons: Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG)
======================================
Median Overall Survival from start of Treatment (OST):
——————————————————————
10.3 months – 6/1/2003 Antineoplastons – Protocol – BT-11 BRAIN STEM GLIOMA 2004 (Pg. 51)
======================================
Median Overall Survival from start of Treatment (OST):
——————————————————————
10.3 months – Antineoplastons
6/1/2003 – Protocol – BRAIN STEM GLIOMA (Pg. 51)
======================================
Median Survival (MST):
——————————————————————
8.5 months – 3/15/1999 standard radiation therapy in combination with chemotherapy (RAT) (Mandell et al.) (6/1992–10/1997) children with newly diagnosed diffuse intrinsic BRAIN STEM TUMORS: results of pediatric oncology group
======================================
Median time to Death:
——————————————————————
8.5 months – ARM 1: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 3/15/1999 (Pg. 58)
======================================
Median Overall Survival from start of Treatment (OST):
——————————————————————
8.5 months – 3/15/1999 ARM 1: Median time to Death: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
======================================
Median Overall Survival from Diagnosis (OSD):
——————————————————————
8.5 months – 3/15/1999 ARM 1: Median time to Death: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
======================================
Median Survival for Recurrent Tumors:
——————————————————————
8 months – 2002 Protocol – recurrent high-grade glioma Low dose thalidomide and temodar. (Phuphanich, et al.) (Pg. 58)
======================================
Median time to Death:
——————————————————————
8 months – ARM 2: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992 – 10/1997) 3/15/1999 (Pg. 58)
======================================
Median Overall Survival from Diagnosis (OSD):
——————————————————————
8 months – 3/15/1999 ARM 2: Median time to Death: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
======================================
Median Overall Survival from start of Treatment (OST):
——————————————————————
8 months – 3/15/1999 ARM 2: Median time to Death: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
======================================
Progression-Free Survival (PFS):
——————————————————————
7 months – Antineoplastons Protocol – subgroup very difficult to treat recurrent diffuse intrinsic BRAIN STEM GLIOMA (Pg. 52)
======================================
Progression-Free Survival (PFS):
——————————————————————
7 months – 6/1/2003 Antineoplastons – Protocol – BT-11 BRAIN STEM GLIOMA 2004 (Pg. 51)
======================================
Median Survival:
——————————————————————
7 months – 2003 Antineoplastons: Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pg. 99)
======================================
Progression-Free Survival (PFS):
——————————————————————
7 months – Antineoplastons Protocol – subgroup very difficult to treat recurrent diffuse intrinsic BRAIN STEM GLIOMA (Pg. 52)
======================================
Median Survival:
——————————————————————
6.4 months – 2003 Antineoplastons: Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 Special Exception (SE) (Pg. 99)
======================================
Median time to Disease Progression:
——————————————————————
6 months – ARM 1: 3/15/1999 Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
======================================
% of responding Patients didn’t develop Progression:
——————————————————————
43% – 6/1/2003 Antineoplastons – Protocol – BT-11 – BRAIN STEM GLIOMA 2004 (Pg. 51)
======================================
Patients with high-grade, recurrent and progressive BRAINSTEM GLIOMAS: Progression-Free Survival (PFS) at 6 months:
——————————————————————
39% – 3/2006 Antineoplastons: BRAINSTEM GLIOMA (BSG) (Pgs. 40 and 44-45)
======================================
Patients with Recurrent Tumors Survive no more than, despite standard treatment:
——————————————————————
6 months – (Pgs. 40 and 45-46)
======================================
Median time to Disease
Progression:
——————————————————————
6 months – ARM 1: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992 – 10/1997) 3/15/1999 (Pg. 58)
======================================
Median Progression-Free Survival (PFS):
——————————————————————
5.28 months – 3/2006 Antineoplastons: BRAINSTEM GLIOMA (BSG) (Pg. 45)
======================================
Median time to Disease Progression:
——————————————————————
5 months – ARM 2: 3/15/1999 Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
� � � � � � � � � � � � � � � � �

� � � � � � � � � � � � � � � � �
Burzynski: Complete Response, Partial Response, Stable Disease, Progressive Disease, Objective Response, and Response:
https://stanislawrajmundburzynski.wordpress.com/2013/07/04/burzynski-complete-response-partial-response-stable-disease-progressive-disease-objective-response-and-response/
� � � � � � � � � � � � � � � � �
Burzynski: Progression-Free Survival:
https://stanislawrajmundburzynski.wordpress.com/2013/07/04/burzynski-progression-free-survival/
� � � � � � � � � � � � � � � � �

Advertisement